We further compared the mRNA level of cancer stemness markers in AZD4547-treated (2 μM) vs. non-treated control L3.6 cells and found that CD24, CD44, and CD133, were dramatically down-regulated upon AZD4547 treatment (Figure 1F). This evidence concerns the gene CD44 and cancer.